P/B
0,5
Curis
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
$2.5M
Market Cap • 9/11/2026
2000
(26 years)
Founded
2000
(26 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
0,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
4
EPS
—
Market Cap
Market Cap
2,5M
EV
-1,5M
EV/Revenue
-0,4
EV/EBITDA
0,2
EV/EBIT
0,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-988,6%
Total Yield
-988,6%
Payout
0%
Retained Earnings
-1,3B
Profitability
Gross Margin
100%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
589,2%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
6,6%
% Goodwill
47,3%
ROE
458,7%
ROIC
—
Growth
CAGR Revenue 5Y
-15,9%
CAGR Op. Income 5Y
-22%
CAGR Net Income 5Y
-9,1%
CAGR EPS 5Y
-18,8%
CAGR OCF 5Y
-0,5%
Leverage
N.D./EBITDA
0,5
Debt/Equity
0%
Current Ratio
0,5
Quick Ratio
0,4
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!